Many studies have documented that patients under the age of 40 years have worse survival rates than their older counterparts.25 The triple-negative subtype is an aggressive subtype with poor survival16 and a worldwide breast cancer burden of 10% – 20% of invasive breast cancers.27,28 The majority of patients, in this study, had luminal A subtype which was also the most common finding in those younger than 40 years in a study by Zhiyang et al.29 Hormone receptor-positive subtypes have more treatment options available in terms of hormone-directed therapy.16 This evidence concerns the gene NR4A1 and breast cancer.